



AN **INNOVATIVE**
WORLD LEADER IN HIGH
PERFORMANCE POLYMER
SOLUTIONS

We bring **transformational & sustainable**
solutions which address world material
challenges every day

VICTREX PLC
PRELIMINARY RESULTS
6 DECEMBER 2021

EXECUTIVE DIRECTORS



Jakob Sigurdsson
Chief Executive Officer



Richard Armitage
Chief Financial Officer



Martin Court
Chief Commercial
Officer



A woman with long, wavy brown hair, wearing a dark blue business suit over a light blue shirt, is standing next to a white electric car. She is looking down at a charging cable or port on the car. The background is a blurred city street with buildings and other vehicles. A blue triangular graphic element is in the bottom right corner, containing the text "A SOLID & SUSTAINABLE RECOVERY".


**A SOLID &
SUSTAINABLE RECOVERY**



SAFELY NAVIGATING COVID-19 CHALLENGES

- ▶ Health, safety and well-being of our employees the highest priority
- ▶ Strong customer service levels, >90% On Time In Full (OTIF)
- ▶ Global Return to Site in most regions (backed by Flexible Working)
- ▶ Embedded a Zero Accident, Zero Incident culture

(recordable injury frequency rate down 45%)



ZERO INCIDENTS
ACCIDENTS

HIGHLIGHTS

A solid & sustainable recovery



FURTHER ENHANCED ESG STRATEGY

- Signatory to Science Based Target initiative (SBTi), reflecting 2030 net zero goal (Scope 1 & 2)
- New ESG criteria added to Executive remuneration

- **SOLID & SUSTAINABLE RECOVERY; FY VOLUMES +25%**
 - FY sales volume up 25%, driven by improving end-markets
 - Double-digit YoY growth in Electronics, Energy & Industrial, VAR
 - Improvement in Automotive with volumes +18% despite Semiconductor challenges
 - Medical revenue up 3% as elective surgeries gradually return
 - 9% increase in new application targets
- **PBT UP 21%; STRONG VOLUME GROWTH & COST MANAGEMENT**
 - Underlying PBT up 21% at £91.7m; reported PBT up 46% at £92.5m
 - GM stable at 54.0% despite weaker mix, FX and inventory unwind
- **FURTHER PROGRESS IN 'MEGA-PROGRAMME' GROWTH PIPELINE**
 - Strong validation of PEEK technology through sale of Magma interest to TechnipFMC; opportunities in traditional & new energy including hydrogen transportation
 - Good progress in PEEK Knee clinical trial; 10 patients now implanted
 - Meaningful revenue of c£1m in PEEK Gears
 - Further progress in E-mobility, with 50% increase in development agreements
 - Good progress in Trauma joint developments
- **STRONG CASH GENERATION UNDERPINNING INVESTMENT & RETURNS**
 - FY 2021 available cash £99.9m** underpinning c£40m capex; FY 2022 investment focused on China
 - Operating cash conversion¹ 100%
 - Civil construction progressing on plan for new PEEK facility in China; commissioning in 2022
 - Post-Brexit inventory unwind benefiting cashflow; total inventory down £28m to £70m
 - Dividends returned to pre-COVID-19 levels & special dividend of 50p/share

¹ Alternative performance measures are defined in the Appendix on slide 37

^{**} Available cash of £99.9m excludes £12.5m of cash ring-fenced in the Group's Chinese subsidiaries and includes £37.5m in 95-day notice deposit accounts

STRONG VOLUME, REVENUE & PBT GROWTH:

- FY 2021 volumes +25%, revenue +15%
- Stable gross margin at 54.0% (up 50bps)
- Lower under-absorption vs FY 2020 (£10m vs £13m)
- Total overheads excluding bonus down 2%
- Underlying PBT +21% at £91.7m
- Dividends at pre-COVID levels & 50p/share special dividend

Year ended 30 September


	FY 2021 £m	FY 2020 £m	Change %	Change (constant currency) ¹ %
Revenue	306.3	266.0	15%	20%
Gains/(Losses) on foreign currency net hedging*	4.9	(1.5)	-427%	
Gross profit	165.3	142.4	16%	20%
<i>Gross margin %</i>	54.0%	53.5%	+50bps	
Overheads**	(72.7)	(66.4)	9%	9%
Exceptionals	0.8	(12.0)	-107%	-107%
Interest	0.0	0.0		
Share of loss of associate	(0.9)	(0.5)		
Underlying profit before tax¹	91.7	75.5	21%	30%
Profit before tax	92.5	63.5	46%	60%
Underlying earnings per share (pence)	83.4	75.3	11%	NA
Earnings per share (pence)	84.3	62.6	35%	NA
Dividend per share	109.56p	46.14p	137%	NA

* Gains/(Losses) on foreign currency contracts, when net hedging is applied on cash flow hedges, are disclosed separately within gross margin on adoption of IFRS 9.

** Excluding exceptional items of £0.8m (FY20: loss of £12.0m)

FY 2021 vs FY 2020

PBT bridge...



STRONG PBT GROWTH


- PBT offset by under-absorption, raw materials, weaker sales mix, FX and bonus
- Improving asset utilisation (lower under-absorption of fixed costs vs FY 2020)
- All Employee Bonus Scheme/LTIP c£9m incremental in FY 2021

ASP & MARGIN

Weaker mix,
stable margin

£/kg Average
selling price (ASP)

Gross margin
(GM) %




FY ASP AT £70/kg (FY 2020: £76/kg)

- Strong improvement in most Industrial-end markets
- Slower Medical recovery, impacting sales mix

GM STABLE DESPITE MIX, FX, INVENTORY UNWIND

- H2 2021 GM 54.0%, flat against H1 2021
- FY GM of 54.0% up 50bps vs FY 2020

MARGIN RECOVERY



OPPORTUNITY FOR MID-TERM MARGIN RECOVERY

- *Asset utilisation continuing to improve (reduced under-absorption of fixed costs)*
- *FY 2022 GM expected to be impacted by higher energy & raw material costs, FX*

CURRENCY

Sizeable FY22
headwind...

	2021				2020		Change
	Reported	Before Impact of deals	Currency Spot Impact	Constant currency ¹	As reported	Before Impact of deals	Constant currency ¹
	£m	£m	£m	£m	£m	£m	£m
Revenue	306.3	306.3	10.6	316.9	266.0	266.0	20%
Loss on foreign currency net hedging	4.9	-	-	-	(1.5)	-	
Gross profit	165.4	160.5	10.0	170.5	142.3	143.8	20%
Gross margin %	54.0%			53.8%	53.5%	54.1%	
Profit before tax	92.6	87.7	10.4	98.0	63.5	65.0	61%

Exchange rates

		2021	2020	2022	Exchange rate sensitivity ⁴
Effective rates ² :	\$/£	1.28	1.26	1.36	£5.1m
	€/£	1.14	1.11	1.15	£5.7m
Weighted average spot rates ³ :	\$/£	1.36	1.27	1.34	
	€/£	1.14	1.13	1.18	

- FY 2021 currency headwind £4m at PBT
- FY 2022 currency headwind c£8m-£11m at PBT; c80% hedging in place


¹ Alternative performance measures are defined in the Appendix on slide 37

² Effective rates (includes the impact of hedging)

³ Management estimate of impact on 2022 full year forecast PBT from a 5% movement in weighted average spot exchange rates (before the impact of hedging)

INVENTORY

Good progress on inventory unwind...



	FY19	FY20	FY21	FY21 v. FY19
	£m	£m	£m	£m
Raw materials	16.3	25.4	11.7	(4.6)
Work in progress	12.4	17.2	11.2	(1.2)
Finished goods	63.5	55.9	47.3	(16.2)
Total Inventory	92.2	98.5	70.2	(22.0)

- **FY 2021 INVENTORY £70m**

- *Post Brexit inventory unwind down £28m (from peak inventory in FY 2020)*
- *Maintain short-term inventories c£70-£80m to reflect raw materials, supply chain uncertainties & customer service levels*

- **STRONG SERVICE LEVELS FOR CUSTOMERS**

- *OTIF (On time in full) >90% in FY 2021*

CHINA

Investment to
underpin
future growth...



c1million safety
hours to date

ON TRACK: COMMISSIONING 2022

- Civil construction completed
- c80% of FY 2021 capex in China & additional capability
- Further develop customer relationships

CAPITAL INVESTMENT

Targeted investment



FY 2022 ANTICIPATED TOTAL CAPEX > £60m

CASH

Strong cash generation...

	FY2021 £m	FY2020 £m
Operating profit before exceptionals	92.6	76.0
Depreciation & amortisation	22.7	20.9
EBITDA	115.3	96.9
Change in working capital	19.6	4.8
Capital expenditure	(41.9)	(24.9)
Operating cash flow	93.0	76.8
Operating cash conversion	100%	101%
Interest received	0.2	0.3
Interest paid	-	(0.3)
Tax	(8.6)	(17.2)
Exceptional income/(cost)	0.8	(12.0)
Other	(0.2)	(3.1)
Free cash flow	85.2	44.5
Acquisitions and Investments	-	(4.9)
Loan to associated undertaking	(3.8)	-
Dividends	(51.6)	(39.9)
Cash received from NCI	5.6	0.0
Other	4.3	1.5
Net cash flow	39.7	1.2
Exchange differences	(0.4)	(0.6)
Net cash at 1st October	73.1	72.5
Net cash at 30th September	112.4	73.1
Other financial assets	37.5	0.0
Cash and cash equivalents	74.9	73.1
	112.4	73.1

SUPPORTING GROWTH & DIVIDEND RETURNS

- *Operating cash conversion 100%*
- *High capex year £42m*
- *Cash benefit from inventory unwind*
- *Dividends returned to pre-COVID levels & special dividend declared*
- *Strong mid-term dividend return opportunities*

PERFORMANCE UPDATE

MEDICAL

~ 13 million implanted devices
worldwide use Invibio PEEK-OPTIMA™ polymers



INDUSTRIAL & MANUFACTURING & ENGINEERING

100+ million machines
operating using Victrex solutions



AEROSPACE

20,000+ aircraft
Have Victrex solutions onboard



ELECTRONICS

4+ billion mobile devices
use APTIV™ Acoustic Film



ENERGY

75+ million VICTREX™ PEEK seals
in use



AUTOMOTIVE

500+ million Automotive applications
made with VICTREX™ PEEK



INDUSTRIAL UPDATE



AUTOMOTIVE: APPLICATION GROWTH & END-MARKET RECOVERY

- *FY 2021 Automotive +18%; new application growth & end market recovery*
- *Meaningful revenue of £1m+ for Gears; Growing e-mobility pipeline*



AEROSPACE: LIMITED IMPROVEMENT; LONG TERM OPPORTUNITIES INTACT

- *FY 2021 Aerospace -20%; sequential improvement (+8% H2 2021 vs H1 2021)*
- *Long term programmes remain robust: Loaded Brackets & Aero Structures*
- *Strong progress with OEMs on thermoplastic composite programmes*



ENERGY & INDUSTRIAL: IMPROVING ENERGY, NEW INDUSTRIAL SOLUTIONS

- *FY 2021 Energy & Industrial up 22% (Energy up 11%)*
- *New PEEK solutions in food, fridge, robotics*



ELECTRONICS: STRONG PERFORMANCE ACROSS APPLICATIONS

- *FY 2021 Electronics +33%; new Semicon, 5G & Home Appliance opportunities*
- *Benefiting from home-working culture*


VALUE ADDED RESELLERS (VAR)

- *FY 2021 volumes +39%; supply chain normalising after restocking effect*

CORE APPLICATION UPDATE




FY volumes +33%



Semiconductor, Mobile Devices, Home Appliances



FY volumes +18%



Powertrain, Braking, Gears (polymer)



FY volumes +22%
(Energy +11%, Industrial +30%)




Compressors, Robotics, Food & drink

GOOD GROWTH IN NEW APPLICATION TARGETS
PIPELINE OF MATURE ANNUALISED REVENUE +9% (£325m vs £299m)

GEARS

A growing opportunity & meaningful revenue delivered...

- **MEANINGFUL REVENUE £1M+**
- **OPPORTUNITY ACROSS ICE & EV**
- **4 PROGRAMMES "ON THE ROAD" (PARTS)**
- **>20 DEVELOPMENT PROGRAMMES**



E-MOBILITY

Now a mega-programme



- **FOCUSED ON NEXT GENERATION 800V+**
- **CURRENT 10g PEEK/CAR TO >100g/PEEK OPPORTUNITY**
- **GOOD GROWTH IN DEVELOPMENT PROGRAMMES**

E-MOBILITY

Why PEEK fits...



Higher performance



Dielectric properties



Processing cost / less scrap



Durability and efficiency



Temperature resistance




Safety

Reduced noise vibration



Lower carbon intensity vs enamel



GROW NEW APPLICATIONS

- Wire, coatings, e-motor

TRANSLATE EXISTING APPLICATIONS

- Brakes, bearings, washers, pumps, gears

2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028

DEVELOPMENT & VALIDATION PHASE

COMMERCIALISATION & EXPANSION

MAGMA

Strategic investment by
TechnipFMC, preparing for
scale-up...

TECHNIP FMC ACQUISITION OF MAGMA

- Strong validation of technology, based on Victrex PEEK
- Strong supply relationship & retained expertise
- Continued support for TFMC scale-up (new Brazilian facility)
- Deliver qualification pipe in FY 2022

OPPORTUNITY IN ENERGY TRANSITION

- Separate Enoflex partnership, small Victrex investment



MEDICAL UPDATE



FY 2021 REVENUE +3% TO £51.1m

- H2 2021 up 8% vs H1 in CFX (Asia + 19% for FY in CFX)
- Spine down 8% (down 3% in CFX) reflecting COVID impact
- Growth in all regions (constant FX)
- Preparing for Porous PEEK FDA approval / HA approvals in EU

GOOD PROGRESS IN NON-SPINE; +19% (now 45% of revenue)

- Growth across all segments: Trauma, Dental, Cardio, Ortho
- Trauma +26%, CMF +25%
- Significant opportunities in Cardio devices (+30% in FY 2021, now a £5m business)
- Dental de-prioritised; clinical proposition remains strong (additional data in 2022)



MEDICAL STRATEGY

SPINE



Grow near-term meaningful revenues from PEEK-OPTIMA HA-Enhanced (FY19), Spinal Rods and porous PEEK cages

NON-SPINE



Further grow non-Spine revenues (currently 45% of Medical revenue) & grow Cardio & CMF

MEGA-PROGRAMMES



Deliver meaningful revenues from mega-programmes; focus on Trauma plates & Knee

BY 2027 INVIBIO SOLUTIONS SEEK TO TREAT A PATIENT EVERY 15-20 SECONDS

PEEK KNEE

Good progress in clinical trial
(Maxx Orthopedics partnership)

GOOD PROGRESS AT 6-MONTH STAGE

- 10 implants to date (6 India, 4 Belgium) despite COVID impact
- Up to two-year timeline, c30 patients
- Opportunity for new partnerships (major Knee companies)
- c\$10bn total knee replacement market




MEGA-PROGRAMMES

Strong growth pipeline...

E-mobility:
Gears:
Dental:

KEY CHANGES:

mega-programme classification
meaningful revenue
non-mega-programme classification



Size of bubble
= potential annual revenue in peak year
(all bubbles are indicative only)



< £20m



£20-50m



> £50m
(all bubbles are indicative only)

Position and colour of bubble
= time to meaningful revenue:



Horizon 1 (0-2 years)



Horizon 2 (2-5 years)



Horizon 3 (5 years +)

PIPELINE MILESTONES

PROGRAMME	REVENUE STATUS	FY 2021 MILESTONES	FY 2022 FOCUS
MAGMA	Meaningful (£1m-£2m)	<ul style="list-style-type: none"> • TechnipFMC acquisition for scale up • Support for Brazil qualification 	<ul style="list-style-type: none"> • Brazil qualification programme • Enoflex: explore new energy opportunities
AERO BRACKETS	Meaningful (£1m-£2m)	<ul style="list-style-type: none"> • Retained meaningful revenue despite COVID impact 	<ul style="list-style-type: none"> • <u>Build repeat orders, increase revenue beyond £2m</u> • Progress eVTOL opportunities
GEARS	Meaningful (£1m-£2m)	<ul style="list-style-type: none"> • Meaningful revenue secured • Pipeline & development programme build 	<ul style="list-style-type: none"> • <u>Drive revenue for Gear Solutions (polymer & parts)</u> • Commercialise development agreements (existing & new)
DENTAL	< £1m	<ul style="list-style-type: none"> • Good revenue growth • Continued mid-term clinical data (Malo) 	<ul style="list-style-type: none"> • De-prioritise & explore adoption via OEM partners • Further build clinical evidence including 5+ year data
TRAUMA	< £1m	<ul style="list-style-type: none"> • New In2Bones partnership • Manufacturing ready • Asia opportunities 	<ul style="list-style-type: none"> • Multiple plate launches (US & Asia) • First OEM deployment • Manufacturing collaboration
AERO STRUCTURES	< £1m	<ul style="list-style-type: none"> • First prototype revenues • Continued OEM collaborations 	<ul style="list-style-type: none"> • Support Clean Sky2 assembly prototypes • <u>Achieve meaningful revenue (prototype revenue)</u>
KNEE	n/a	<ul style="list-style-type: none"> • First implant, 10 to date • 6 month follow up stage successful 	<ul style="list-style-type: none"> • Progress clinical trial • Build additional partnerships/OEM agreements
E-MOBILITY	n/a	<ul style="list-style-type: none"> • Mega-programme potential • 50% increase in development programmes 	<ul style="list-style-type: none"> • Wire coating OEM launch • Early commercial revenues • Progress to support production scale up in FY 2022

OUR PURPOSE



Sales to Aerospace support 3x CO2 saving vs Victrex scope 1 & 2 emissions*




80,000 tonne annual CO2 saving in Europe for selected applications**



Improved union rates in Spine and Trauma vs metal applications***

We Bring Transformational & Sustainable Solutions That Address World Material Challenges Every Day



*Based on 10kg of PEEK replacement for metal, IATA carbon reduction & climate change 2018

**Based on European annual mileage for passenger cars using PEEK based vacuum pump and thrust washer applications vs metal

***Victrex data on file



ESG


WE BRING TRANSFORMATIONAL & SUSTAINABLE SOLUTIONS THAT ADDRESS WORLD MATERIAL CHALLENGES EVERY DAY

ENVIRONMENT

ACHIEVE NET ZERO CARBON EMISSIONS

Minimise use of resources (energy, waste, water) used in our own operations

2021: 28,454 tonnes
2030: Net Zero



GOVERNANCE

ESG Centre of Excellence

- Increase disclosures and reporting
- Further validation of ESG strategy
- Signed up to SBTi Targets



SUSTAINABLE SOLUTIONS

BRING ENVIRONMENTAL & SOCIETAL BENEFITS



Develop and deliver sustainable polymer solutions that provide environmental and societal benefits evidenced by data

2021: 50% revenue
2030: 70% revenue

SOCIAL

HAVE A POSITIVE IMPACT ON THE COMMUNITIES WHERE WE WORK



STEM INSPIRATION

Science, Technology, Engineering & Maths

Inspire the next generation: increase annual contacts reached

2021: 1,600
Goal: 2,500



COMMUNITY ACTIVITY

Maintain strong community engagement (cumulative hours target)

2021: 3,500
2030: 10,000



FEMALES IN LEADERSHIP (top two grades)

Enhance inclusion & diversity

2021: 10%
2030: 40%

SAFETY, HEALTH & WELLBEING

Achieve a Zero accident & Zero incident culture

Recordable Frequency Injury Rate

Current: 0.7
Goal: Zero



- Achieve carbon net zero emissions by 2030
- Increase the use of our sustainable & recyclable products which support CO₂ reduction
- Minimise resources (Carbon, Waste and Water) used in our operations
- Increase employee and community engagement on social responsibility

END-MARKET OUTLOOK

FY 2022*



ELECTRONICS



MEDICAL



ENERGY & INDUSTRIAL



AUTOMOTIVE



AEROSPACE



KEY

OPTIMISTIC



NEUTRAL



CAUTIOUS



* Indicative outlook for our markets for FY 2022

FY 2022 OUTLOOK

“Focused on year on year growth”

- Further recovery in end-markets, offset by VAR
- Improved sales mix
- Cost headwinds: FX, raw materials, energy, innovation
- Improving asset utilisation

SUMMARY:

‘STATE OF THE NATION’

- **PEOPLE:** Innovative culture – “safely deliver with speed & agility”
- **OPERATIONS:** Improving & extending asset base
- **CUSTOMERS:** Strong service levels through COVID
- **PIPELINE:** Strong core business; mega programme milestones
- **ESG:** Sustainable products; environmental & societal benefit
- **CASH:** Supporting investment & shareholder returns

**We Bring Transformational & Sustainable
Solutions That Address World Material
Challenges Every Day**






APPENDIX


GROUP END MARKETS

FY 2021: 4,373 tonnes
FY 2020: 3,492 tonnes

Volume by Region



Volume by Industry




* Medical volume reflects both non-implantable and implantable volumes

MEDICAL: KEY MARKETS


FY 2021: £51.1m

FY 2020: £49.7m

Revenue by Region (live FX)



Revenue by Market (live FX)



BUSINESS UNIT INCOME STATEMENTS

	2021				2020		
	Reported	Exc deals	Currency Spot Impact	Constant currency ¹	As reported	Exc Deals	Constant currency ¹
	£m	£m	£m	£m	£m	£m	£m
Industrial							
Revenue	255.2	255.2	7.7	262.9	216.3	216.3	22%
Loss on foreign currency net hedging	3.5	-	-	-	(0.9)	-	
Gross profit *	119.7	116.2	7.1	123.3	99.3	100.2	25%
Gross margin %	46.9%	45.5%		46.9%	45.9%	46.3%	
Medical							
Revenue	51.1	51.1	2.8	53.9	49.8	49.8	9%
Loss on foreign currency net hedging	1.4	-	-	-	(0.7)	-	
Gross profit *	45.6	44.2	2.9	47.1	43.0	43.7	8%
Gross margin %	89.2%	86.5%		87.4%	86.4%	87.8%	

¹ Alternative performance measures are defined in the Appendix on slide 37

BALANCE SHEET

	FY 2021	FY 2020
	£m	£m
PPE and intangible assets	330.5	300.1
Investment in associated undertakings	11.4	12.3
Financial assets held at fair value through profit and loss*	12.7	8.0
Inventories	70.3	98.5
Cash**	112.4	73.1
Trade receivables and other assets	63.8	50.0
Retirement benefit asset	12.3	7.5
Trade payables and other liabilities	(101.7)	(68.5)
Equity shareholders' funds	511.7	481.0

* Financial assets held at fair value through profit and loss ("FVTPL")

**Includes £12.5m of cash ring-fenced in the Group's Chinese subsidiaries, and £37.5m in 95-day deposit accounts

DEFINITIONS

ALTERNATIVE PERFORMANCE MEASURES:

- 1) Constant currency metrics are reached by applying current year (FY 2021) weighted average spot rates to prior year (FY 2020) transactions. Gains and losses on foreign currency net hedging, are shown separately in the Income Statement and are excluded from the constant currency calculation;
- 2) Underlying PBT is profit before exceptional items and tax;
- 3) Operating cash conversion is operating profit before exceptional items adjusted for depreciation and amortisation, working capital and capital expenditure / operating profit before exceptional items;
- 4) Available cash is cash and cash equivalents plus other financial assets (cash invested in term deposits greater than three months in duration) less cash ring-fenced in the Group's Chinese subsidiaries which is committed to capital investment or additional capability and therefore not available to the wider group;
- 5) Return on Capital Employed (ROCE) is profit after tax / total equity attributable to shareholders at the year end;
- 6) Operating overheads is made up of sales, marketing and administrative expenses before exceptional items; and
- 7) Underlying EPS is earnings per share based on profit after tax but before exceptional items divided by the weighted average number of shares in issue.

CAPITAL ALLOCATION

Investment for growth remains the priority

CAPEX

- Normalised capex c5-6% of sales
- Periodic investment in capacity & innovation

M&A / INVESTMENT

- Developing capability
- Invest to support mega-programmes & end-market growth

REGULAR DIVIDENDS

- Average growth c5% over last 10 years
- Grow in line with EPS

SPECIAL DIVIDENDS

- c50% of net cash >£85m threshold
- 50p/share minimum

#1 PEEK EXPERTS

First to commercialise PEEK, with unmatched knowledge and experience



INFORMATION & CONTACTS

Andrew Hanson
Director of IR &
Corporate Communications

+44 (0) 1253 898121
+44 (0) 7809 595831
ir@victrex.com
www.victrexplc.com

AEROSPACE



ELECTRONICS



ENERGY &
INDUSTRIAL



MEDICAL



AUTOMOTIVE

POLYMER MANUFACTURING

Delivering the key PEEK & PAEK materials with No.1 manufacturing capacity of 7,150 tonnes




DIFFERENTIATE THROUGH INNOVATION TO CREATE NEW MARKETS




POLYMER

Producing new grades including for Additive Manufacturing (3D Printing)



PRODUCT FORMS

Manufacturing product forms: Pipes, Films, Fibres and Composite Tapes



PARTS & COMPONENTS

Developing new applications for PEEK, PAEK and Thermoplastic Composites

UNDERPIN: SAFETY, SUSTAINABILITY

- Health & safety
- Sustainable business with sustainable products



GLOBAL CAPABILITY

800+

Employees

40+

Countries served by Victrex across our markets

c£2bn

Market Value

- FTSE 250 Company
- c£300m Revenue



INVESTMENT IN INNOVATION

c5-6% **c£150m**

of annual sales invested in R&D

Invested in manufacturing facilities in the last 5 years

NEW CAPABILITIES

- Partnerships
- Strategic Alliances
- Polymer Innovation Centre
- Acquisitions
- Composites Manufacturing
- Additive Manufacturing